Search for: "Kay Laboratories, Inc. v. District Court"
Results 1 - 6
of 6
Sorted by Relevance
|
Sort by Date
27 Mar 2008, 1:29 am
The case is titled Bella Bella, Inc. v. [read post]
1 Dec 2017, 5:59 am
Abbott Laboratories and AbbVie Inc. [read post]
21 Oct 2009, 6:13 am
– response to IAM article suggesting pharmaceutical companies will subsidise Rio 2016 (IP tango) EU: India, Brazil to file WTO complaint against the EU over ‘seizures’ of pharma drug consignments (Spicy IP) US: PhRMA supports follow-on biologics regulatory pathway providing 12 years of data exclusivity (Patent Docs) US: Senators Orrin Hatch, Barbara Mikulski, Michael Enzi and Kay Hagan write in support of 12-year data exclusivity period (Patent Docs) US: New… [read post]
21 Oct 2009, 5:13 am
- response to IAM article suggesting pharmaceutical companies will subsidise Rio 2016 (IP tango) EU: India, Brazil to file WTO complaint against the EU over 'seizures' of pharma drug consignments (Spicy IP) US: PhRMA supports follow-on biologics regulatory pathway providing 12 years of data exclusivity (Patent Docs) US: Senators Orrin Hatch, Barbara Mikulski, Michael Enzi and Kay Hagan write in support of 12-year data exclusivity period (Patent Docs) US: New England Journal of… [read post]
21 Oct 2009, 5:13 am
- response to IAM article suggesting pharmaceutical companies will subsidise Rio 2016 (IP tango) EU: India, Brazil to file WTO complaint against the EU over 'seizures' of pharma drug consignments (Spicy IP) US: PhRMA supports follow-on biologics regulatory pathway providing 12 years of data exclusivity (Patent Docs) US: Senators Orrin Hatch, Barbara Mikulski, Michael Enzi and Kay Hagan write in support of 12-year data exclusivity period (Patent Docs) US: New England Journal of… [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex… [read post]
